|
Dr. Perry has served as a director of Targeted Genetics since November 2005. Dr. Perry is the Chief Development Officer for VIA Pharmaceuticals. Prior to joining VIA, Dr. Perry co-founded Extropy Pharmaceuticals, Inc., a pediatric specialty pharmaceutical company. Dr. Perry was Chairman and Chief Executive Officer of Extropy from June 2003 to March 2005. From February 2002 to March 2003, Dr. Perry was President and Chief Executive Officer of Pharsight Corp., a publicly traded software and consulting services firm integrating scientific and business decision criteria in computer-based models for optimizing drug development. From October 2000 to February 2002, Dr. Perry was Worldwide Head, Global R&D at Baxter BioScience, with responsibility for the company’s R&D organization, from basic discovery through product launch and life cycle management. From 1994 to 2000, Dr. Perry was an executive with Sandoz / Novartis Pharma, where his responsibilities included global regulatory affairs and drug registration. He also was President and Chief Executive Officer of two wholly owned Novartis biotech subsidiaries, SyStemix Inc. and Genetic Therapy Inc. Prior to joining Sandoz / Novartis, Dr. Perry held executive positions in regulatory affairs with Syntex Corp. and Schering-Plough Corp. Previously, he held management positions with BioResearch Laboratories, Inc., a contract research organization, and also practiced veterinary medicine. Dr. Perry received his BSc (Hon.) degree in Physics and his DVM degree from the University of Guelph. He also earned his PhD in Biomedical Science, with a specialty in Cardiopulmonary Pharmacology, from the University of Guelph. From 1997 to 1998 Dr. Perry was sponsored by Novartis in the Executive Management Program at Harvard University. He is a Fellow of the American College of Veterinary Pharmacology and Therapeutics. | 